SHR-1905

N/A

Report date: 2026/02/11 20:01:36

Base Information

Drug NameSHR-1905
Drug Alias NameSHR-1905AIO-001GSK-5784283
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicNasal Polyps +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Hengrui Pharmaceutical Co LtdGlaxosmithkline PlcAtridia Pty Ltd +[4] 
Inactive CompaniesAiolos Bio Inc
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicNasal Polyps +[6] 
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A